| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Aug 1, 2011Investigational Second-Generation Device Reinforces Medtronic's Commitment to Innovative Implantable Cardiac Devices Designed for Use in MRI Environment
MINNEAPOLIS, Aug 01, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval for its Investigational Device Exemption (IDE) application...
-
Jul 25, 2011Presented at CVIT by Principal Investigator Shigeru Saito, One-Year Data from RESOLUTE Japan Support Company's PMDA Submission for Product Approval
MINNEAPOLIS, Jul 25, 2011 (BUSINESS WIRE) -- TheResolute(R) drug-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT), showed superiority to Boston Scientific Corp.'s Taxus(R) DES on the primary...
-
Jul 21, 2011Distance Runners from Around the World Who Benefit from Medical Technology to Run Medtronic Twin Cities Marathon Events this Fall
MINNEAPOLIS, Jul 21, 2011 (BUSINESS WIRE) -- Twenty-five long-distance runners who benefit from medical technology will be honored as "Medtronic Global Heroes" when they run the Medtronic Twin...
-
Jul 11, 2011Patient Enrollment in U.S. Clinical Trial of Renal Denervation with Symplicity(R) Catheter System(TM) for Treating Resistant Hypertension to Start Soon
MINNEAPOLIS, Jul 11, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT), announced today that the U.S. Food and Drug Administration (FDA) has conditionally approved the protocol for SYMPLICITY...
-
Jul 8, 2011Update to July 2009 Letter to Healthcare Professionals
MINNEAPOLIS, Jul 08, 2011 (BUSINESS WIRE) -- As part of its ongoing commitment to keep patients and physicians informed about product performance and safety, Medtronic, Inc. (NYSE: MDT) is issuing...